Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA

Biohaven Ltd.

Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).
FDA accepted troriluzole NDA for spinocerebellar ataxia with Priority Review; PDUFA date in 3Q 2025.
BHV-1300 (IgG degrader) achieved up to 84% reduction of total IgG in Phase 1; Phase 2 in Graves' disease expected mid-2025.
Next-gen TRAP degraders BHV-1400 (IgAN) and BHV-1600 (PPCM) advanced; Phase 1 completion expected 1H 2025.
Multiple pipeline milestones expected: BHV-7000 MDD topline 2H 2025, BHV-8000 Parkinson's study initiation 1H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.